FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000390031> ?p ?o ?g. }

• W2000390031 endingPage "24" @default.
• W2000390031 startingPage "19" @default.
• W2000390031 abstract "The efficacy and safety of bevacizumab and docetaxel were evaluated in women who developed recurrent epithelial ovarian, fallopian, or peritoneal cancer within 12 months of platinum-based therapy.Patients received docetaxel (40 mg/m(2)) on days 1 and 8 and bevacizumab (15 mg/kg) on day 1 of a 21-daycycle. Primary endpoint was 6-month progression-free survival (PFS).Forty-one patients were evaluable for PFS and 38 for best response; 46% had platinum-free intervals (PFI) of <6 months and 54% between 6 and 12 months. The 6-month PFS was 43.9% (95% confidence interval (CI(95%))=28.6-58.2%). Median PFS (months) was 5.2 (CI(95%)=4.4-7.2) for all patients, 6.2 (CI(95%)=4.1-7.4) for patients with PFI <6 months, and 5.1 (CI(95%)=3.0-7.2) for those with PFI ≥ 6 months. Twenty-two patients showed overall response (CR+PR) (57.9%; CI(95%)=40.8-73.7%), and 32 showed clinical benefit (CR+PR+SD) (84.2%; CI(95%)=68.8-94.0%). For those with complete or partial responses, median duration of response was 4.8 months (0.7-14.5). Median overall survival was 12.4 months (CI(95%)=10.0-21.9). The most common grade 3/4 adverse events (AEs) were neutropenia (14.6% of patients), followed by leukopenia, fatigue, metabolic, and gastrointestinal, with 66% showing any grade 3/4 toxicity. Most common AEs of any grade were gastrointestinal (93%), fatigue (73%), and pain (73%). Four (10%) patients developed hypertension, 1 a gastrointestinal perforation, and another a colovesicular fistula.Bevacizumab and docetaxel administered in patients with recurrent ovarian cancer is an active regimen without new unanticipated toxicities. This combination should be an option for further study or clinical use in recurrent ovarian cancer." @default.
• W2000390031 created "2016-06-24" @default.
• W2000390031 creator A5001733858 @default.
• W2000390031 creator A5002576207 @default.
• W2000390031 creator A5006894236 @default.
• W2000390031 creator A5020590235 @default.
• W2000390031 creator A5044655732 @default.
• W2000390031 creator A5045131302 @default.
• W2000390031 creator A5062151371 @default.
• W2000390031 creator A5074540364 @default.
• W2000390031 creator A5075384296 @default.
• W2000390031 creator A5085606987 @default.
• W2000390031 date "2013-07-01" @default.
• W2000390031 modified "2023-09-27" @default.
• W2000390031 title "A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy" @default.
• W2000390031 cites W1959506700 @default.
• W2000390031 cites W1964740590 @default.
• W2000390031 cites W1967619561 @default.
• W2000390031 cites W1975393618 @default.
• W2000390031 cites W1977093846 @default.
• W2000390031 cites W1980212074 @default.
• W2000390031 cites W1980499812 @default.
• W2000390031 cites W1982410899 @default.
• W2000390031 cites W1998198982 @default.
• W2000390031 cites W2000763913 @default.
• W2000390031 cites W2001403404 @default.
• W2000390031 cites W2001989538 @default.
• W2000390031 cites W2004494623 @default.
• W2000390031 cites W2018929154 @default.
• W2000390031 cites W2024074772 @default.
• W2000390031 cites W2041142804 @default.
• W2000390031 cites W2043276557 @default.
• W2000390031 cites W2050103821 @default.
• W2000390031 cites W2056278185 @default.
• W2000390031 cites W2077376170 @default.
• W2000390031 cites W2079449334 @default.
• W2000390031 cites W2085527076 @default.
• W2000390031 cites W2096521047 @default.
• W2000390031 cites W2098766256 @default.
• W2000390031 cites W2105651363 @default.
• W2000390031 cites W2113122060 @default.
• W2000390031 cites W2113361623 @default.
• W2000390031 cites W2120530458 @default.
• W2000390031 cites W2129610375 @default.
• W2000390031 cites W2135947389 @default.
• W2000390031 cites W2137741807 @default.
• W2000390031 cites W2140607155 @default.
• W2000390031 cites W2143556151 @default.
• W2000390031 cites W2159569440 @default.
• W2000390031 cites W2167224460 @default.
• W2000390031 cites W3028515504 @default.
• W2000390031 cites W4237782428 @default.
• W2000390031 cites W4241512656 @default.
• W2000390031 cites W4293241248 @default.
• W2000390031 cites W2090479345 @default.
• W2000390031 doi "https://doi.org/10.1016/j.ygyno.2013.04.049" @default.
• W2000390031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23623830" @default.
• W2000390031 hasPublicationYear "2013" @default.
• W2000390031 type Work @default.
• W2000390031 sameAs 2000390031 @default.
• W2000390031 citedByCount "26" @default.
• W2000390031 countsByYear W20003900312013 @default.
• W2000390031 countsByYear W20003900312014 @default.
• W2000390031 countsByYear W20003900312015 @default.
• W2000390031 countsByYear W20003900312016 @default.
• W2000390031 countsByYear W20003900312018 @default.
• W2000390031 countsByYear W20003900312019 @default.
• W2000390031 countsByYear W20003900312020 @default.
• W2000390031 countsByYear W20003900312021 @default.
• W2000390031 countsByYear W20003900312023 @default.
• W2000390031 crossrefType "journal-article" @default.
• W2000390031 hasAuthorship W2000390031A5001733858 @default.
• W2000390031 hasAuthorship W2000390031A5002576207 @default.
• W2000390031 hasAuthorship W2000390031A5006894236 @default.
• W2000390031 hasAuthorship W2000390031A5020590235 @default.
• W2000390031 hasAuthorship W2000390031A5044655732 @default.
• W2000390031 hasAuthorship W2000390031A5045131302 @default.
• W2000390031 hasAuthorship W2000390031A5062151371 @default.
• W2000390031 hasAuthorship W2000390031A5074540364 @default.
• W2000390031 hasAuthorship W2000390031A5075384296 @default.
• W2000390031 hasAuthorship W2000390031A5085606987 @default.
• W2000390031 hasConcept C121608353 @default.
• W2000390031 hasConcept C126322002 @default.
• W2000390031 hasConcept C141071460 @default.
• W2000390031 hasConcept C197934379 @default.
• W2000390031 hasConcept C203092338 @default.
• W2000390031 hasConcept C2776694085 @default.
• W2000390031 hasConcept C2777063308 @default.
• W2000390031 hasConcept C2777802072 @default.
• W2000390031 hasConcept C2780427987 @default.
• W2000390031 hasConcept C2780739268 @default.
• W2000390031 hasConcept C2780873365 @default.
• W2000390031 hasConcept C2781190966 @default.
• W2000390031 hasConcept C31760486 @default.
• W2000390031 hasConcept C44249647 @default.
• W2000390031 hasConcept C535046627 @default.
• W2000390031 hasConcept C71924100 @default.
• W2000390031 hasConcept C90924648 @default.

• next